Research company Aptahem reports a lower operating loss during the first quarter compared with the corresponding period last year. Operating revenue also decreased slightly.Operating revenue amounted to SEK 0.57 million (0.64). Operating profit, as well as profit before and after tax, amounted to SEK -1.4 million (-2.0).Earnings per share amounted to -0.07 (-0.16).Cash and cash equivalents amounted to SEK 1.3 million at the end of the quarter (1.3).After the end of the quarter, Aptahem carried out a rights issue that brought the company about SEK 3.15 million before issue costs. The issue was subscribed to at about 23.7 percent.CEO Mikael Lindstam says that the company continues to work on positioning the drug candidate Apta-1 ahead of the next development phase and that interest in the project remains strong.Aptahem, MkrQ1 2026Q1 2025Change (%)Revenue0.60.6-10.4Operating profit-1.4-2.0Profit before tax-1.4-2.0Net profit-1.4-2.0Earnings per share-0.07-0.16